A specially designed drug prevented laboratory mice from developing heart failure after heart attacks, according to new ...

Cellipont Bioservices and Secretome Therapeutics are set to enter a collaboration in the manufacture of the latter’s cellular therapy, STM-01. The collaboration will see Cellipont offering technology ...

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

Tom Nolan reviews this week’s research Exercise for 30 minutes three times a week on an exercise bike for a month; then make the sessions an hour long and add resistance training with two sets of ...

However, the benefits of beta-blockers in “stiff heart” heart failure are less clear. This condition, also known as heart ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Ms. Andor will lead the Company’s expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan (TNX-103) for the treatment of pulmonary hypertension ...

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive interim data ...

Both incident and recurrent heart failure hospitalization risk is associated with post-traumatic stress disorder among patients with CAD.

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...